Carmine N. Stengone - May 24, 2024 Form 4 Insider Report for Contineum Therapeutics, Inc. (CTNM)

Role
CEO and President, Director
Signature
/s/ Peter Slover, Attorney-in-Fact
Stock symbol
CTNM
Transactions as of
May 24, 2024
Transactions value $
$0
Form type
4
Date filed
5/29/2024, 05:59 PM
Previous filing
Apr 4, 2024
Next filing
Jul 3, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTNM Stock Option (right to buy) Award $0 +285K $0.00 285K May 24, 2024 Class A Common Stock 285K $15.76 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Options granted under the Issuer's 2024 Equity Incentive Plan. 25% of the option shares vest on April 5, 2025, and the remainder vests in equal monthly installments over the next 36 months thereafter, subject to the Reporting Person's continuous service.